Litcius/Paper detail

Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials

Jingjing Gu, Lei Shi, Xiaowen Jiang, Jianhua Wen, Xiaoming Zheng, Cai Hu, Weidong Zhang

2022Cancer Immunology Immunotherapy27 citationsDOIOpen Access PDF

Topics & Concepts

NivolumabAtezolizumabDurvalumabPembrolizumabMedicineIpilimumabOncologyInternal medicineLung cancerAdverse effectPneumonitisCancerImmunotherapyLungCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisLung Cancer Research Studies
Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials | Litcius